The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases.

anti-tumor immunity autoimmunity dendritic cells (DC) tertiary lymphoid organs (TLO) tertiary lymphoid structures (TLS)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 27 05 2024
accepted: 23 09 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 1 11 2024
Statut: epublish

Résumé

Tertiary Lymphoid Structures (TLS) are organized aggregates of immune cells such as T cells, B cells, and Dendritic Cells (DCs), as well as fibroblasts, formed postnatally in response to signals from cytokines and chemokines. Central to the function of TLS are DCs, professional antigen-presenting cells (APCs) that coordinate the adaptive immune response, and which can be classified into different subsets, with specific functions, and markers. In this article, we review current data on the contribution of different DC subsets to TLS function in cancer and autoimmunity, two opposite sides of the immune response. Different DC subsets can be found in different tumor types, correlating with cancer prognosis. Moreover, DCs are also present in TLS found in autoimmune and inflammatory conditions, contributing to disease development. Broadly, the presence of DCs in TLS appears to be associated with favorable clinical outcomes in cancer while in autoimmune pathologies these cells are associated with unfavorable prognosis. Therefore, it is important to analyze the complex functions of DCs within TLS in order to enhance our fundamental understanding of immune regulation but also as a possible route to create innovative clinical interventions designed for the specific needs of patients with diverse pathological diseases.

Identifiants

pubmed: 39483484
doi: 10.3389/fimmu.2024.1439413
pmc: PMC11526390
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1439413

Informations de copyright

Copyright © 2024 Reste, Ajazi, Sayi-Yazgan, Jankovic, Bufan, Brandau, Bækkevold, Petitprez, Lindstedt, Adema and Almeida.

Déclaration de conflit d'intérêts

FP is a consultant for SOTIO Biotech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Mariana Reste (M)

Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Kristi Ajazi (K)

Department of Immunotechnology, Lund University, Lund, Sweden.

Ayca Sayi-Yazgan (A)

Department of Molecular Biology and Genetics, Faculty of Science and Letters, Istanbul Technical University, Istanbul, Türkiye.
Department of Life Sciences, Centre for Inflammation Research and Translational Medicine, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom.

Radmila Jankovic (R)

Faculty of Medicine, Institute of Pathology, University of Belgrade, Belgrade, Serbia.

Biljana Bufan (B)

Department of Microbiology and Immunology, University of Belgrade - Faculty of Pharmacy, Belgrade, Serbia.

Sven Brandau (S)

Experimental and Translational Research, Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany.

Espen S Bækkevold (ES)

Department of Pathology, Oslo University Hospital-Rikshospitalet, Oslo, Norway.

Florent Petitprez (F)

Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom.

Malin Lindstedt (M)

Department of Immunotechnology, Lund University, Lund, Sweden.

Gosse J Adema (GJ)

Radiotherapy & OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands.

Catarina R Almeida (CR)

Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH